Vaxcyte, Inc.
PCVX
$44.70
-$0.82-1.80%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -657.20M | -547.50M | -509.63M | -463.93M | -507.65M |
| Total Depreciation and Amortization | 19.85M | 19.14M | 17.63M | 15.85M | 14.01M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 81.44M | 57.90M | 62.80M | 50.35M | 37.95M |
| Change in Net Operating Assets | 13.77M | 10.91M | -30.58M | -54.90M | -14.35M |
| Cash from Operations | -542.15M | -459.55M | -459.78M | -452.63M | -470.04M |
| Capital Expenditure | -78.58M | -104.61M | -133.84M | -119.16M | -146.20M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -156.36M | -1.17B | -1.30B | -1.89B | -1.32B |
| Cash from Investing | -234.94M | -1.27B | -1.43B | -2.01B | -1.46B |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 15.58M | 1.54B | 1.65B | 2.46B | 2.46B |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -11.07M | -16.43M | -16.28M | -14.29M | -13.54M |
| Cash from Financing | 4.51M | 1.52B | 1.63B | 2.45B | 2.45B |
| Foreign Exchange rate Adjustments | 3.61M | -2.25M | -4.46M | 426.00K | -8.61M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -768.96M | -211.71M | -264.45M | -9.36M | 505.27M |